TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

Completed · Phase 2

Conditions studied: Skin and Subcutaneous Tissue Bacterial Infections, Gram-Positive Bacterial Infections

In brief

The purpose of this study is to evaluate safety, tolerability, pharmacokinetic characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens.

Key facts

Study ID
NCT03964493
Run by
TenNor Therapeutics Limited
People needed
120
Starts
2019-04-20
Expected to finish
2020-09-28
Last updated by the study team
2023-12-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.